RxDoctor Payments Data

Lalasa Valasareddi, MD

Internal Medicine · Brooklyn, NYNPI 1912936675

Payments from drug & device makers

$1,055in general payments, 2019–2025

Across 39 payments — averaging $27.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$236
  • AstraZeneca$222
  • Lilly USA, LLC$203
  • Amgen$167
  • Exact Sciences$75
  • Bayer$64
  • plus $88 from 3 others

What the payments were for

  • Food & beverage$1,055100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie2$236
AstraZeneca11$222
Lilly USA, LLC9$203
Amgen7$167
Exact Sciences3$75
Bayer3$64
GSK2$45
Novo Nordisk1$22
Merck1$21

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,055 in reported general payments places this provider in the 70th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$55,457
Medicare patients
116
Services billed
694

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin88$106,628
EliquisApixaban87$106,494
JanuviaSitagliptin Phosphate75$95,305
EntrestoSacubitril/Valsartan61$90,028
TrulicityDulaglutide52$86,252
FarxigaDapagliflozin Propanediol61$63,775
OzempicSemaglutide36$45,734
LinzessLinaclotide44$41,801
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog60$26,004
XareltoRivaroxaban20$16,356
TradjentaLinagliptin20$15,621
Albuterol Sulfate HfaAlbuterol Sulfate320$11,822
Breo ElliptaFluticasone/Vilanterol22$11,138
Nifedipine ErNifedipine265$8,537
Diclofenac Sodium ErDiclofenac Sodium93$7,136

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$21$95,30575 claims
Lilly USA, LLCTrulicity$203$86,25252 claims
AstraZenecaFarxiga$222$63,77561 claims
Novo NordiskOzempic$22$45,73436 claims
AbbVieLinzess$236$41,80144 claims
GSKBreo Ellipta$45$11,13822 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →